John Valliant, Chief Executive Officer at Fusion Pharmaceuticals Inc. (FUSN), sold 1,500 shares at $6.96 ($10K) on 2022-03-14, disclosed to the SEC on 2022-03-16.
Scheduled sale ($10k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.96 | 1,300 | $9K | 86.5% |
| 2 | $7.12 | 100 | $712 | 6.8% |
| 3 | $6.99 | 100 | $699 | 6.7% |
| Total | $6.97 avg | 1,500 | $10K | 100% |
| Filing → |
| FUSN | SELL | 2022-04-13 | $432K | — | Filing → |
| FUSN | SELL | 2022-04-08 | $16K | — | Filing → |
| FUSN | SELL | 2022-04-05 | $29K | — | Filing → |